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Abstract 
Objective: To show how systematic ethical evaluation of public health policy may reveal issues of 
moral significance for critical examination. 
Method: Using Australia's human papillomavirus (HPV) vaccination program as an exemplar and 
adopting an approach outlined elsewhere, we determine whether conditions of effectiveness, 
proportionality, necessity and least infringement, and public justification, are met such that any 
breach of autonomy or justice principles associated with this intervention can be defended. 
Conclusions: While the HPV vaccine itself may be efficacious, some aspects of the program lack 
sufficient moral justification and raise concerns around procedural and social justice and gender 
equity. 
Implications: Public health interventions deploying new technologies against new targets – such as 
vaccines against cancer and chronic illness – require approaches crafted to their specific risk-benefit 
profiles that have carefully considered the ethical issues involved. Systematic ethical reflection is a 
useful tool for this. 
 
 
While growing interest in the ethics of public health, particularly around health promotion, is 
exploring its moral assumptions, the moral values relevant to specific public health interventions are 
rarely made explicit. An ethical perspective centred on the important moral principles of 
beneficence, respect for autonomy, and justice, posits the moral authority of much public health 
policy in the principle of beneficence. Public health interventions seek to benefit the community, 
exemplified in utilitarian approaches (seeking the greatest good for the greatest number). This 
nonetheless creates moral tensions, particularly with principles of respect for autonomy and 
justice.1–6 
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Using the approach to resolving these tensions of Childress et al.2 to critique Australia's HPV 
vaccination program, we conclude that parts of the program are difficult to morally justify. More 
importantly, we demonstrate how issues of moral significance, otherwise overlooked, are exposed. 
Objective 
Our objective in this paper is to demonstrate how a process of structured moral reflection can bring 
important issues to light, allowing their proper inclusion in policy deliberations. 
Approach 
As background, we briefly discuss some important criticisms of utilitarianism in public health before 
outlining Australia's recently introduced HPV vaccination program. We then evaluate key aspects of 
the program using the approach of Childress et al.2 They proposed that where “there is conflict 
between the general moral considerations that are generally taken to instantiate the goals of public 
health – producing benefits, preventing harms, and maximising utility – and those that express other 
moral commitments”[p173], certain justificatory conditions (effectiveness, proportionality, necessity 
and least infringement, and public justification) should be met to merit the public health values 
prevailing. 
Utilitarianism in public health 
Public health authorities have historically taken an outcome-oriented approach to maximise utility 
(the ratio of benefits over harms). This approach may be uncontroversial. Mass immunisation 
programs have such an impressive record – smallpox eradicated, the impact of polio, measles, 
diphtheria and other infections dramatically reduced7– that the broad-brush approaches that 
efficiently delivered the population coverage needed for disease control could be justified given the 
clear public benefit and the necessity for urgent action and absence of realistic alternatives. 
However, strategies of highly selective framing and simplistic or emotional messages, while once 
acceptable as they sought an important social good, are difficult to transpose to situations where 
the trade-offs are not so clearly agreed. As the conditions targeted by public health become more 
complex, interventions entail risk-benefit calculations that are inevitably more uncertain, making any 
disregard for the principles of respect for autonomy or justice harder to defend.8,9 This disregard is 
seen as utilitarian approaches legitimise only one value (the pre-selected utility on offer), and may 
overlook benefits such as non-discrimination or social justice that, while harder to measure, are 
important to society. These considerations are especially relevant where interventions target issues 
that lack imperatives of urgency or necessity, and where any evidence-base supporting health 
promotion undertakings is weak.10 Also, people's decisions to participate may be only self-
regarding, making interventions that require individuals’ active cooperation, but which use only 
perfunctory consent procedures, difficult to justify. 
The human papillomavirus 
Genital infections caused by HPV are the most common sexually transmitted infections (STIs) in the 
world. The vast majority of infections are self-limiting. It is only persistent infection with high-risk 
strains of HPV that is linked to anogenital and other cancers and is a necessary causal factor for 
cervical cancer. 
Worldwide cervical cancer affects about 500,000 women a year and causes about 270,000 deaths. 
Australia's rates are among the world's lowest, due largely to its cervical screening program, though 
certain under-screened groups retain incidence many times the national average.11–13 
Importantly, half of HPV-related cancers are non-cervical and one quarter occurs in men. In men 
who have sex with men, the risk of HPV-related anal cancer is equal to that of cervical cancer in 
unscreened women, and the correlation between oropharyngeal cancers (whose rising incidence 
mirrors that of oral sex) and high-risk HPV is even higher than that of cervical cancer.14,15 
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The HPV vaccine 
A prophylactic vaccine, Gardasil®, offers protection against acquisition of four HPV strains: 16 and 
18, responsible for about 70% of cervical cancers, and 6 and 11, which cause 90% of genital warts. It 
induces strong antibody responses in girls and boys up to 15 years old. Clinical trials of 15–26 year 
old females have demonstrated efficacy of 90–100% in per-protocol populations against vaccine-
type virus acquisition, persistent infection and cervical cancer precursor lesions, with an average of 
three years follow up.16 Much lower efficacy was seen in intention-to-treat analyses.17 Importantly, 
the projected lowering of cervical cancer risk associated with HPV vaccination translates to only a 
small benefit in absolute terms for screened women, reducing an individual's lifetime risk from 
0.86% to 0.30–0.47%.18 
Australia's HPV vaccination program 
Australia was among the first countries to license Gardasil in mid-2006 following intense media 
coverage of the miracle of the ‘cancer vaccine’ and the key role played in its development by an 
Australian researcher, Dr Ian Frazer, and an Australian company, CSL. It is noteworthy, however, that 
in November 2006, the Pharmaceutical Benefits Advisory Committee (PBAC), an independent 
statutory body that evaluates new pharmaceutical products for public subsidy, initially rejected CSL's 
application for inclusion of Gardasil into Australia's immunisation program, citing inadequate data 
(particularly on duration of immunity and the long-term impact on cancer) and lack of cost-
effectiveness.19 A public outcry ensued and the government requested that the PBAC urgently 
review its decision. That same month the PBAC received a revised submission from CSL, after which 
it reversed its initial decision.19 
The government then announced a national program of vaccination of schoolgirls aged 12–13, the 
first country in the world to do so, along with a two year catch-up period for females aged 13–26. As 
part of this program, girls in the first year of high school in NSW were given a sealed Human 
Papillomavirus (HPV) Vaccination Parent Information Kit to take home. At the time that the program 
began this was available only in English. It contained a brief leaflet entitled ‘Protecting your daughter 
against cervical cancer’ and a question and answer page (Parents are referred elsewhere for further 
information). It also contained a consent form for a parent or guardian to sign and return within one 
week. 
Semiotics of HPV vaccination information 
The information provided in this kit and indeed the entire HPV vaccination campaign stressed the 
risk of cervical cancer, the urgent need for and the benefit of HPV vaccination. Certain facts implying 
high risk –“anyone who has ever had sexual contact could have HPV”, “people do not know they 
have the infection”20 and there being “no cure for HPV infection”21– were given prominence over 
the fact that the vast majority of HPV infections resolve naturally and do not lead to cancer. All girls 
were regarded as at equal risk. The small reduction in absolute risk for screened women afforded by 
the vaccine was not mentioned; alternative strategies including delayed vaccination or compliance 
with current screening recommendations were either not referred to at all or not discussed in terms 
of their relative risk reduction. 
No mention was made of the high efficacy against genital warts. Condoms were referred to in a 
rather disparaging way (they only “offer limited protection as they do not cover all the genital 
skin”21) and there was no reference to other prevention measures nor to sexual health more 
broadly. 
Ethical evaluation using Childress's justificatory conditions 
Any program promoting a new vaccine requires as a minimum an appropriate level of data regarding 
the efficacy and safety of the product. As outlined earlier, the HPV vaccine promised high efficacy 
against acquisition of vaccine-type virus. Vaccine-related adverse events – pain, erythema, swelling 
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and pruritis at the injection site, and fever, headache, arthralgia, fatigue, and myalgia – were minor; 
rare or long-term harms may yet emerge.16 
However, while the short-term utility of the vaccine may be established our interest here is whether 
the overall program initiated in late 2006 meets Childress's justificatory conditions. This distinction is 
important as different aspects of any public health intervention may draw upon information of 
variable amount and quality, and may entrench, challenge or override different moral values. 
Effectiveness 
This program of universal vaccination slotted into the national immunisation schedule is likely to 
achieve high uptake, however it had an expressly-stated goal of reducing cervical cancer. It is 
difficult to provide robust evidence in advance for the likely effectiveness of any cancer prevention 
program.16,22 Results from limited follow-up of study populations using surrogate endpoints may 
not translate into long-term effectiveness of widespread administration in real-world populations; 
modelling is imprecise and not all relevant variables can be foreseen.17 Many questions remain 
unanswered, key among them the duration of protection (with possible need for booster 
vaccination), the implications of poorer screening program performance resulting from reduced 
disease prevalence, and the risk of reduced screening participation, or increased risk behaviour, 
from a perception of adequate protection by the vaccine alone.7 
Proportionality 
The notion of proportionality requires that the benefits should exceed harms. Such analysis depends 
on the appropriate selection, definition and evaluation of the harms and benefits of public health 
programs, and, critically, on an understanding of how they impact differently on different people. 
Benefits to vaccine recipients of reduced incidence of screen-detected cervical abnormalities and of 
genital warts are expected to be realised early (though screening is still required given the role of 
non-vaccine-type high-risk strains in cervical cancer). No vaccine-related serious adverse events had 
been seen.16 
Taking a broader perspective on the benefits and harms of the program, however, raises important 
questions. It is not known whether policy deliberations canvassed alternative program design 
offering additional benefits or considered any potential for the program's utilitarian approach to 
further disadvantage vulnerable subgroups or be discriminatory. 
We note that the burden of vaccination falls on girls, while the benefit from reduced viral prevalence 
extends to males. Furthermore, vaccinating both sexes, while perhaps adding little to cervical cancer 
reduction, would directly benefit males, offering protection against genital warts and oropharyngeal 
and anogenital malignancies (a benefit particularly for men who have sex with men, who are at 
greatest risk but not readily identifiable for targeted vaccination prior to risk acquisition). Another 
benefit may be reducing male sub-fertility as the virus has been isolated in semen and linked with 
reduced sperm motility.23 
The decision not to vaccinate boys, if indeed any consideration was given to postponing the program 
until efficacy data in males was available, perpetuates discriminatory gender-role stereotypes. In 
reinforcing the idea that STIs are a ‘women's issue’ it permits boys to take less responsibility for their 
behaviour, even though their sexual behaviour (with males generally having a higher number of 
previous partners and partnering with younger females) contributes to the risk of HPV acquisition 
for females. Given that we already have evidence that a range of reproductive and sexual health 
concerns in young people are responsive to school-based programs, the failure to genuinely engage 
boys in this program is a missed opportunity to address gender inequity.24 
Regarding differential program impact on different subgroups, one concern is that high overall 
vaccine acceptance could mask low uptake in those women most at-risk of cervical cancer (and thus 
most likely to benefit from vaccination.) These include those likely to be under-screened and those 
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who live in areas with significant levels of high school absenteeism (who may potentially miss 
vaccination days); there appear to be no programmatic features addressing this. 
Necessity and least infringement 
These conditions require that any public health intervention is necessary and that it involve the least 
possible infringement of important values. Many HPV vaccines are being researched and may prove 
a valuable addition to existing cervical cancer control measures. Given the latter's established 
success, however, urgently introducing a program of mass administration of a prototype vaccine 
appears unjustified by any necessity. 
Public justification 
Childress proposes that in order to be morally defensible, public health interventions should be 
publicly justified. This attention to transparency and accountability would ideally involve considered 
community consultation around ethical and social issues. By way of comparison, public 
communications surrounding this program, focused exclusively on cervical cancer and an allegedly 
urgent need to tackle it, were characterised by an exaggerated perception of risk and themes of a 
noble cause and civic responsibility. Given the complexity of issues raised by a program vaccinating 
one sex against an STI-induced cancer (leaving aside the issue of a minor's capacity to consent), a 
more inclusive public discourse would seem to be required to satisfy this condition. 
Conclusion 
Assessing Australia's HPV vaccination program against Childress's framework of justificatory 
conditions challenges its moral reasoning. The conditions of necessity and public justification cannot 
be demonstrably met, and many questions remain around effectiveness. Regarding proportionality, 
the apparent lack of attention to gender equity and social justice issues are of concern. This process 
has demonstrated how systematic ethical reflection can bring forward a range of issues relevant to 
public health interventions for critical evaluation. 
Implications 
While vaccines against infectious disease have traditionally raised little controversy, new targets, 
given the rising burden of chronic disease, and new biomedical technologies bring moral hazards. 
Evaluations of benefits and harms for vaccines against STI-induced cancers, and for emerging 
vaccines against non-infectious chronic disease (such as degenerative diseases25) and even non-
disease entities (risk factors for cardiovascular disease, or nicotine, for example26,27) are much less 
straightforward and community consensus cannot be assumed. Careful examination of the medical, 
socio-cultural, and moral issues that may arise with their dissemination is required, especially if the 
decision to have a particular vaccine is largely self-regarding. Systematic ethical reflection can 
provide a mechanism for this and invite confidence in public health authority. 
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